Drugs / OCS-05
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04762017 | Feb 2021 → Sep 2024 | optic neuritis | Oculis | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCS-05 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04762017 ↗ |
| Known as | BN201 | “OCS-05 (aka BN201) is a peptidomimetic that binds to serum glucocorticoid kinase-2 (SGK2), displaying neuroprotective activity.” PMID 36991169 ↗ Mar 2023 |
| Route | Intravenous | “Once daily IV infusions” NCT04762017 ↗ |
| Target | SGK2 | “binds to serum glucocorticoid kinase-2 (SGK2)” PMID 36991169 ↗ Mar 2023 |